Cytosorbents Corporation CTSO

Company Overview

Cytosorbents Corporation is a U.S.-based critical care immunotherapy and blood purification company focused on technologies designed to reduce excessive inflammation and remove harmful substances from blood during life-threatening conditions and complex surgical procedures. The company operates primarily in the medical device and biotechnology industries, with a focus on extracorporeal blood purification therapies used in intensive care, cardiac surgery, organ support, and infectious disease management. Its principal revenue driver has historically been sales of the CytoSorb blood purification cartridge, particularly in international markets where the product has received regulatory approvals for use in critically ill patients.

The company was founded in 1997 and is headquartered in Princeton, New Jersey. Cytosorbents evolved from an early-stage polymer adsorption technology developer into a commercial-stage medical technology company with products marketed across Europe and other international regions. The company’s positioning is based on proprietary polymer adsorption technology intended to remove inflammatory mediators, drugs, and toxins from blood while integrating with existing extracorporeal circulation systems such as dialysis machines, heart-lung machines, and ECMO platforms. Public disclosures indicate the company has pursued a strategy centered on expanding regulatory clearances, growing international distribution, and developing applications for perioperative and critical care medicine.